<DOC>
	<DOCNO>NCT00675844</DOCNO>
	<brief_summary>Extension study subject currently participate protocol ACH443-015 ACH443-018 .</brief_summary>
	<brief_title>An Open Label Treatment Protocol Provide Continued Elvucitabine Treatment</brief_title>
	<detailed_description>HIV-1-infected , clinically stable , treatment-na√Øve adult complete 96-weeks elvucitabine therapy protocol ACH443-015 whose HIV RNA level remain 50 copies/mL 92-week assessment protocol ACH443-015 subject complete 48-weeks elvucitabine therapy protocol ACH443-018 continue maintain HIV-1 RNA viral load baseline level upon entry protocol ACH443-018</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Zalcitabine</mesh_term>
	<criteria>Subject must successfully complete 96 week elvucitabine therapy Protocol ACH443015 OR subject complete 48weeks elvucitabine therapy protocol ACH443014A / 018 . Subject experience viroligic rebound define section 5.6.1.3 protocol ACH443015 . Subject exceed baseline HIV1 RNA level Week 44 measure protocol ACH443014A / 018 Subject experience drugrelated Grade 3 4 rash drug relate grade 3 4 laboratory toxicity Grade 3 4 cholesterol , triglyceride , creatinine kinase , LDH .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Extension study</keyword>
	<keyword>HIV-1 infection</keyword>
	<keyword>Treatment Naive</keyword>
</DOC>